Skip to main content
. 2023 Jul 19;9(29):eadg5358. doi: 10.1126/sciadv.adg5358

Fig. 8. Antifibrotic mechanisms of Lip@NCAF and MSCs.

Fig. 8.

(A) Illustration of antifibrotic mechanisms of Lip@NCAF. MEK, mitogen-activated protein kinase kinase. (B) The expressions of p-PDGFR and p-ERK1/2 by WB. RNA levels of Col1a1 (C) and Pdgfrb (D) (n = 5). The levels of TNF-α (E), IL-1β (F), and IL-6 (G) in young and aged mice treated with MSCs and MSCs-Lip@NCAF (n = 6). (H) IF analysis of the lung sections in aged mice injected with MSCs and MSCs-Lip@NCAF expressing GFP for 14 days (n = 6). RNA levels of Cdkn2a (I), Cdkn1a (J), Mmp12 (K), and Mcp1 (L) of lungs in aged mice (n = 6). Data are means ± SD (E) to (G) or means ± SEM (C), (D), and (I) to (L). *P < 0.05 and **P < 0.01.